- In September 2024, Translumina Therapeutics, a prominent coronary stent provider, announced the launch of its operations in the UAE. This move follows their collaboration with the esteemed German Heart Centre to develop advanced drug-eluting stent technologies, including the most extensively studied DES globally, backed by over a decade of research on safety and efficacy
- In July 2024, MicroPort Scientific Corporation revealed that its subsidiary, Shanghai MicroPort Medical (Group) Co., Ltd., obtained market approval from the NMPA for Firesorb, the first next-generation fully bioresorbable cardiac stent. Pre-market studies indicated that Firesorb demonstrated performance comparable to that of permanent drug-eluting stents in key clinical metrics, such as success rates and late lumen loss
- In May 2024, Global healthcare leader Abbott announced the introduction of the XIENCE Sierra, an everolimus-eluting coronary stent system, in India. This launch followed the system's regulatory approval from the Central Drugs Standard Control Organisation (CDSCO) in February of the same year
- In May 2022, Medtronic plc, a global frontrunner in healthcare technology, announced that it received approval from the U.S. Food and Drug Administration (FDA) for the Onyx Frontier drug-eluting stent (DES). This stent represents the latest advancement in the Resolute DES family, utilizing the same best-in-class platform as the Resolute Onyx DES, but with an improved delivery system designed to enhance deliverability and performance in challenging cases
- In October 2021, The InspireMD CGuard Embolic Prevention Stent System (EPS) received reimbursement approval in France from the National Commission for the Evaluation of Medical Devices and Health Technologies (CNEDIMTS) of the French National Authority for Health (HAS) for the treatment of carotid artery disease (CAD) and stroke prevention
